Gonadorelin 5mg

What is Gonadorelin (5mg)?

Gonadorelin (5mg) is a synthetic decapeptide that mimics the structure of endogenous gonadotropin-releasing hormone (GnRH). It plays a key role in regulating the hypothalamic–pituitary–gonadal (HPG) axis, which controls the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Gonadorelin is commonly used in laboratory research to study the mechanisms of gonadotropin release and reproductive endocrine signaling. This peptide consists of 10 amino acids, with an N-terminal pyroglutamate and a C-terminal glycine amide. These structural features contribute to receptor interaction and biological stability. Gonadorelin has a molecular weight of approximately 1182.3 g/mol. Research-grade preparations typically achieve ≥98% purity, verified using high-performance liquid chromatography (HPLC) and mass spectrometry (MS).

What are the key features of Gonadorelin (5mg)?

Gonadorelin (5mg) is supplied as a lyophilized peptide for controlled laboratory research. Researchers use it in studies of endocrine signaling, gonadotropin release, and receptor pharmacology. Key features of Gonadorelin (5mg) include:

• Peptide sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
• CAS Number: 9034-40-6
• Subcategory: Hormonal & Sexual Health Peptides
• Molecular weight: 1182.3 g/mol
• Chemical Formula: C₅₅H₇₅N₁₇O₁₃
• Purity: Typically ≥98%, verified by HPLC
• Analytical confirmation: Identity confirmed using mass spectrometry (MS)

This product is supplied strictly for laboratory research use only and is not intended for diagnostic, therapeutic, or clinical applications.

How is Gonadorelin (5mg) synthesized?

Gonadorelin is synthesized using solid-phase peptide synthesis (SPPS), a widely used method for constructing peptides with precise amino acid sequences. The synthesis begins with a resin-bound C-terminal glycine amide and proceeds stepwise to incorporate each amino acid in the correct order. After synthesis, the peptide goes through purification by high-performance liquid chromatography (HPLC) to achieve high purity. Mass spectrometry (MS) confirms the peptide's molecular weight and identity. The purified peptide is lyophilized into a powder to minimize degradation and facilitate laboratory handling.

What is Gonadorelin (5mg) being studied for? What are its possible benefits?

Researchers primarily study Gonadorelin for its role in regulating the HPG axis and its ability to modulate gonadotropin release in experimental models. Laboratory studies often evaluate how exposure patterns influence LH and FSH production. Research areas include:

• Pulsatile versus continuous hormone signaling models
• Endocrine feedback loop characterization
• Steroidogenic pathway mapping in gonadal tissues
• Hormone-responsive gene expression analysis
• Receptor sensitivity and desensitization dynamics

Gonadorelin is commonly used to study how temporal hormone patterns influence downstream endocrine responses. Observed biological effects are model-dependent and remain under investigation rather than representing established therapeutic outcomes.

How does Gonadorelin (5mg) work in research studies?

In laboratory systems, Gonadorelin activates pituitary gonadotroph cells, triggering intracellular signaling pathways that regulate LH and FSH synthesis. This activation leads to measurable hormonal responses in both in vitro cultures and animal models. Researchers often manipulate exposure frequency and concentration to evaluate differences in signal transduction and hormonal output. Pulsatile application typically sustains receptor responsiveness, while prolonged exposure may reduce signaling intensity over time. These properties make Gonadorelin a useful tool for studying endocrine timing mechanisms and neuroendocrine regulation.

What dosing information exists for Gonadorelin (5mg)?

Dosing information for Gonadorelin primarily comes from preclinical studies and clinical research protocols examining GnRH-related endocrine signaling. In rodent models, intermittent administration has been studied at approximately 0.1–1 µg/kg at regular intervals to simulate physiologic GnRH pulses. Continuous infusion paradigms in animals have used doses between 1 and 10 µg/kg/hour to examine receptor regulation and hormonal suppression. In vitro studies using cultured pituitary cells typically use concentrations of 1–100 nM to assess intracellular signaling and gonadotropin release. These dosing regimens are experimental and model-specific. No standardized human dosing guidelines exist for standalone research peptide preparations.

How should Gonadorelin (5mg) be stored and handled?

To minimize degradation, Gonadorelin (5mg) should be stored in its lyophilized form at –20 °C or lower. Cold storage preserves peptide structural integrity and reduces the risk of degradation. Protect the vial from light, heat, and moisture, which may affect peptide integrity. After reconstitution with a suitable sterile laboratory solvent, solutions are typically stored at 2–8 °C for short-term use in laboratory experiments. Researchers should prepare small aliquots to minimize repeated freeze-thaw cycles, which can compromise peptide structural integrity. Peptide integrity may vary depending on the choice of solvent and laboratory handling conditions.

Where can I read more research about Gonadorelin (5mg)?

The following peer-reviewed publications provide additional insight into GnRH and gonadorelin research:

1. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25(2):235-275. doi:10.1210/er.2003-0002
2. Flanagan C, Millar R, Illing N. Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions. Reviews of Reproduction. 1997;2(2):113-120. doi:10.1530/revreprod/2.2.113
3. Kaiser UB, Conn PM, Chin WW. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev. 1997;18(1):46-70. doi:10.1210/edrv.18.1.0289
4. Vollaard ES, van Beek AP, Verburg FA, Roos A, Land JA. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin. J Clin Endocrinol Metab. 2011;96(5):1197-1201. doi:10.1210/jc.2010-1991

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.